Stanford University spinout N1 Life has formed a joint venture to further its drug delivery ambitions. The startup is teaming up with Accuredit Therapeutics to create a joint venture, Napoltec, focused on novel drug delivery systems and the progression of drug candidates toward clinical translation.
N1, which was incorporated in 2018, is built on two delivery platforms. One of the platforms enables N1 to conjugate drugs to delivery peptides. The peptide inactivates the drug and protects it from clearance until it reaches the target site, where the linker is cleaved and the payload is released. The approach may improve the pharmacokinetics, safety and efficacy of a range of therapeutic molecules.